Alexion Pharmaceuticals, Inc.
) third-quarter 2013 earnings (excluding special items but
including stock-based compensation expense) of 72 cents per share
beat the Zacks Consensus Estimate by a penny. Earnings were above
the year-ago adjusted earnings by 36%. The year-over-year rise in
earnings was attributable to higher product sales. Including
one-time items, third-quarter 2013 earnings came in at 47 cents
per share, flat year over year.
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Alexion's revenues jumped 36% to approximately $400.4 million in
the third quarter of 2013 driven by strong Soliris sales.
Revenues surpassed the Zacks Consensus Estimate of $396 million.
Adjusted operating expenses climbed approximately 37% to $178.8
million in the third quarter of 2013. The increase was
attributable to a rise in both research and development (R&D)
expenses (up 36%) and selling, general and administrative
(SG&A) expenses (up 37%). The increase in R&D expenses
was attributable to the company's efforts to develop its
Alexion currently has several candidates in clinical development
focusing on different areas. The company is also working on
expanding Soliris' label into additional indications like
Shiga-toxin producing e. coli hemolytic uremic syndrome,
neuromyelitis optica and myasthenia gravis.
Alexion's pipeline also includes asfotase alfa
(hypophosphatasia), ALXN1102/ALXN1103 (hematology), ALXN1101
(molybdenum cofactor deficiency type A) and ALXN1007
(inflammatory disorders). We are impressed by Alexion's efforts
to develop its pipeline.
Concurrent with its earnings release, Alexion announced that ALXN
1101 has been granted a Breakthrough Therapy designation by the
U.S. Food and Drug Administration (FDA) for the above indication.
The designation, which was enacted as part of the 2012 Food and
Drug Administration Safety and Innovation Act, is granted to
potential new treatments for serious or life-threatening diseases
or conditions where the initial clinical data shows that the
treatment has the potential to demonstrate substantial
improvement on one or more clinically significant endpoints
compared to existing treatments. The designation should help
fasten the development and review process of the candidate.
Apart from announcing financial results for the third quarter,
Alexion raised its outlook for 2013. The company raised its
revenue guidance to $1.535-$1.540 billion from the previous
forecast of $1.520-$1.530 billion.
The company also raised its adjusted earnings guidance for 2013
from $2.97-$3.02 per share to $3.02 to $3.04 per share. Soliris
should continue performing well, driving growth at Alexion. The
Zacks Consensus Estimate for 2013 (pre earnings) hinted at
earnings of $2.71 per share on revenues of $1.531 billion.
Alexion carries a Zacks Rank #3 (Hold). Companies such as
Isis Pharmaceuticals, Inc.
) appear to be more attractive, each with a Zacks Rank #1 (Strong